IPO - NEONC TECHNOLOGIES HOLDINGS, INC.

Form Type: 8-K

Filing Date: 2025-03-27

Corporate Action: Ipo

Type: New

Accession Number: 000182912625002097

Filing Summary: On March 6, 2025, NeOnc Technologies Holdings, Inc. filed an Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware, which was approved by its board of directors and stockholders. This amendment includes provisions customary for public companies. The Amended and Restated Bylaws became effective on March 25, 2025, coinciding with the Direct Listing on the Nasdaq Global Market under the ticker 'NTHI'. The amendments address universal proxy rules and clarify solicitation processes for director nominations. On March 25, 2025, the company also issued a press release announcing its Direct Listing, indicating a significant step in its transition to becoming a public entity.

Document Link: View Document

Form Type: 8-A12B

Filing Date: 2025-03-24

Corporate Action: Ipo

Type: New

Accession Number: 000182912625002032

Filing Summary: NEONC Technologies Holdings, Inc. filed Form 8-A for the registration of their common stock under Section 12(b) of the Securities Exchange Act of 1934. The company is based in Delaware and its common stock will be listed on The Nasdaq Stock Market LLC with a par value of $0.0001 per share. This filing is associated with a registration statement (File No. 333-284115) initially filed on January 3, 2025, which details the description of the securities. No additional exhibits were required for this registration as no other securities are registered with Nasdaq. This document was signed by Dr. Thomas Chen, the CEO of the company, on March 24, 2025.

Document Link: View Document

Form Type: S-1/A

Filing Date: 2025-02-26

Corporate Action: Ipo

Type: New

Accession Number: 000182912625001228

Filing Summary: NeOnc Technologies Holdings, Inc., a Delaware-based clinical-stage biopharmaceutical company, has filed an amendment to its S-1 registration statement which details its intention to conduct a direct listing on the Nasdaq Global Market. The prospectus reveals that the company aims to register up to 2,101,313 shares of common stock for resale by stockholders, outlining that this listing is a condition to the offering. The document emphasizes that no underwriter is involved, indicating a novel listing approach where stockholders may sell their shares without firm commitments. The firm details its financial history, having raised approximately $13.1 million through stock sales at $1.25 per share, and subsequently issuing shares at $12.00 and $16.00 during private placements, aiming for gross proceeds totaling around $10 million. NeOnc describes its main products under development—NEO100, targeting brain cancers via intranasal delivery, and NEO212, combining temozolomide with perillyl alcohol. The company has indicated significant clinical trial activity with NEO100 and plans to initiate trials for NEO212. While currently without approved products or significant revenue, NeOnc anticipates increased trial enrollment due to recently approved FDA requests to broaden patient eligibility.

Document Link: View Document

Form Type: S-1/A

Filing Date: 2025-01-31

Corporate Action: Ipo

Type: New

Accession Number: 000182912625000575

Filing Summary: NeOnc Technologies Holdings, Inc. filed an amendment to its Form S-1 registration statement, relating to a proposed direct listing of 2,131,313 shares of its common stock on the Nasdaq Global Market. This listing is a part of a novel method for beginning public trading without a firm-commitment underwritten offer. The document outlines NeOnc's developments in the biotechnology sector, focusing on innovative drug delivery systems for treating brain cancers including two lead products, NEO100 and NEO212. NEO100 is in Phase IIa clinical trials targeting recurrent malignant glioma and skull-based meningioma, while NEO212 has completed preclinical testing and aims to treat primary and secondary brain tumors. The company reported raising approximately $13 million in previous stock sales and intends to sell additional shares at varying prices as part of private placements. NeOnc recognizes the considerable market opportunity in CNS diseases with substantial expected growth in the treatment market. It also highlights its qualifications as an emerging growth company, allowing it to take advantage of reduced public company reporting requirements. Risks related to the listing and trading absence were disclosed, noting that no public market exists currently for its shares. The registration process relies on Nasdaq's approval for listing the common stock under the symbol 'NTHI.'

Document Link: View Document

Form Type: S-1

Filing Date: 2025-01-03

Corporate Action: Ipo

Type: New

Accession Number: 000182912625000013

Filing Summary: NeOnc Technologies Holdings, Inc. is filing for a registration statement under the Securities Act of 1933 for the resale of up to 2,138,004 shares of its common stock by identified stockholders in connection with a direct listing on the Nasdaq Global Market. The offering is unique as it is not underwritten on a firm commitment basis, which sets it apart from traditional IPOs. NeOnc is a clinical-stage biopharmaceutical company focused on the development of treatments for aggressive brain cancers. Its two lead products, NEO100 and NEO212, are in various stages of clinical trials and demonstrate potential in addressing unmet medical needs in the treatment of brain tumors. The company has engaged RBW Capital Partners LLC as a financial advisor for the listing process. NeOnc has raised approximately $13,117,000 from previous stock sales and plans to sell additional shares at private placement prices. In its application to Nasdaq, NeOnc emphasized the high-risk nature of investing in its common stock, given its current lack of revenue and ongoing clinical trials. The offering is contingent upon Nasdaq's approval of the listing, with no assurance provided that it will be approved.

Document Link: View Document

Form Type: DRS/A

Filing Date: 2024-12-10

Corporate Action: Ipo

Type: New

Accession Number: 000182912624008179

Filing Summary: NeOnc Technologies Holdings, Inc. is preparing for a direct listing of its common stock on the Nasdaq Global Market under the symbol 'NTHI'. This document outlines the registration of up to shares of common stock for resale by Registered Stockholders. The company has completed significant fundraises through private placements, allowing the conversion of debt into equity. Currently, NeOnc has no public trading market for its shares, which raises the potential for volatility once listed. The company emphasizes the lack of underwriting in this process, contrasting it with traditional initial public offerings (IPOs). The market for neuro-oncology presents substantial growth, with the global brain tumor drug market expected to reach $4.4 billion by 2029. NeOnc is focused on developing innovative drug delivery methods specifically for intracranial malignancies. They have ongoing clinical trials for their lead products, NEO100 and NEO212, which target challenging brain cancers and metastases. Net losses have been reported, alongside a significant accumulated deficit, highlighting the high-risk nature of investing in the company. The document stresses that the potential listing hinges on approval from Nasdaq, with no guarantees of success.

Document Link: View Document

Form Type: DRS

Filing Date: 2024-10-29

Corporate Action: Ipo

Type: New

Accession Number: 000182912624007038

Filing Summary: NeOnc Technologies Holdings, Inc. is filing a preliminary registration statement on Form S-1 for a direct listing of its common stock on the Nasdaq Global Market. This strategic move follows a series of private transactions where the company raised significant funds. The prospectus outlines that shares are being registered for resale by current stockholders, and no firm commitment underwriting is involved. The company emphasizes that this listing is crucial for its operations and growth, highlighting its focus on developing drug delivery methods for treating aggressive brain cancers. Key products include NEO100, already in Phase IIa trials, and NEO212, set to enter clinical testing. NeOnc, classified as both an 'emerging growth company' and a 'smaller reporting company,' plans to leverage reduced reporting requirements as it pursues growth. However, it also acknowledges substantial ongoing financial losses and the need for continued capital to sustain and expand its research and development efforts. The registration statement confirms the significant market opportunity in the CNS treatment sector, with expectations of continued growth through the upcoming years.

Document Link: View Document